Prestige Consumer Healthcare Inc.: management transactions · United States · SEC (Form 4)

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a U.S.-based consumer healthcare company focused on over-the-counter (OTC) products and selected personal care and wellness brands. Headquartered in Tarrytown, New York, United States, the company has built its portfolio through a brand-acquisition strategy: it has historically purchased recognized brands that were often non-core to larger pharmaceutical or consumer goods companies, then supported them with tighter commercial execution, targeted marketing, and line extensions. The business today operates as Prestige Consumer Healthcare Inc., formerly Prestige Brands, Inc. The company’s model is centered on a diversified portfolio of branded OTC products sold primarily in the United States, Canada, Australia, and certain other international markets. Its portfolio includes well-known names such as Monistat and Summer’s Eve in women’s health; BC and Goody’s in pain relief; Clear Eyes and TheraTears in eye care; DenTek in specialty oral care; Dramamine for motion sickness; Fleet enemas and suppositories; Chloraseptic and Luden’s throat treatments; Compound W wart treatments; Little Remedies pediatric OTC products; Boudreaux’s Butt Paste diaper rash ointment; Nix lice treatment; and Debrox earwax remover. Outside the core North American market, the company also sells Gaviscon in Canada and Hydralyte plus the Fess nasal and sinus care line in Australia. From an equity research perspective, PBH is best understood as a defensive consumer health name rather than a high-growth pharmaceutical company. Its competitive position rests on established brand equity, broad retail distribution, and management’s ability to allocate resources toward the strongest franchises while rationalizing weaker or non-strategic assets. That makes the company attractive to investors seeking resilient demand characteristics, recurring consumer usage patterns, and a portfolio of brands that can be optimized over time. Recent developments indicate continued operational momentum. Prestige reported record fiscal 2025 revenue and earnings, supported by performance in both its North American OTC Healthcare and International OTC Healthcare segments. Management also highlighted portfolio reshaping, with a deliberate shift in sales and branding toward strategic brands and associated non-cash tradename impairment charges on certain non-core assets. For investors in French-speaking markets, the key takeaway is that PBH is a U.S.-listed company on the NYSE, operating in the United States consumer healthcare market, with a defensible brand portfolio and a disciplined, acquisition-and-optimization business model.